Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 4/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609058 | 0.90 | NR1H2 (0.34) | ATXN2HSP90AA1HSP90AB1KCNK3KCNK9 | |
| SCHEMBL608689 | 0.87 | CHRNB2 (0.35) | HSP90AA1HSP90AB1HDAC8MEN1KMT2A | |
| SCHEMBL10145584 | 0.81 | GRM5 (0.36) | ALDH1A1MEN1KMT2AUCHL1USP30 | |
| SCHEMBL608281 | 0.76 | NR1H2 (0.36) | HSP90AA1HSP90AB1HDAC8MEN1KMT2A | |
| SCHEMBL7859303 | 0.76 | ALDH1A1 (0.38) | KCNK3KCNK9HDAC8ALDH1A1MEN1 | |
| SCHEMBL21722953 | 0.68 | GPR119 (0.45) | — | |
| SCHEMBL10145590 | 0.67 | CHRNA3 (0.37) | ALDH1A1 | |
| SCHEMBL10145372 | 0.67 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2AUCHL1USP30 | |
| SCHEMBL7869396 | 0.67 | CNR1 (0.38) | — | |
| SCHEMBL611454 | 0.66 | GPR119 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | ATXN2 2110/4885HSP90AA1 2454/4885HSP90AB1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.